findmyKOL
Clinical trialNCT06386705RecruitingPhase 1Interventional

TSN084 Treating Patients With Advanced Malignant Tumors

SponsorTyligand Bioscience (Shanghai) LimitedEnrollment114Malignant Neoplasm
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jie Wang, MD, PhD

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

    Recruiting
  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
20 Jul 2022
Primary completion
30 Dec 2025
Completion
30 Jun 2026
Last update posted
29 Jul 2024
Registered enrollment
114
Registry id
NCT06386705

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.